This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignees: Johns Hopkins University, Lieber Institute, Inc.. Active years: 2026.
Company Filing History:
1 out of 3,794 
1 out of 9 
Years Active: 2026
Title: Gregory Stachelek: Innovator in RNA Polymerase Inhibition
Introduction
Gregory Stachelek is a notable inventor based in Baltimore, MD (US). He has made significant contributions to the field of biochemistry, particularly in the development of compounds that inhibit RNA polymerase. His work has implications for treating various diseases, including cancer.
Latest Patents
Stachelek holds a patent for "Compounds which inhibit RNA polymerase." This patent features chemical entities, such as compounds or pharmaceutically acceptable salts, that inhibit RNA polymerase I (Pol I). These chemical entities are useful for treating conditions where excessive Pol I activity contributes to the pathology of diseases, such as cancer. The patent also includes compositions containing these entities and methods for their use and production.
Career Highlights
Throughout his career, Gregory Stachelek has worked with prestigious institutions, including Johns Hopkins University and the Lieber Institute, Inc. His research has focused on the biochemical mechanisms that underlie various diseases, leading to innovative therapeutic approaches.
Collaborations
Stachelek has collaborated with Hester Hui Liu, contributing to advancements in their shared field of research.
Conclusion
Gregory Stachelek's work in developing RNA polymerase inhibitors showcases his commitment to advancing medical science and improving treatment options for serious diseases. His contributions are a testament to the impact of innovative research in the field of biochemistry.